All News
Not surprisingly, the week between Christmas and New Year was quiet in terms of clinical trial news. However, there were some announcements. Here’s a look.
Korea Economic Daily, published a story saying that Samsung Group was in talks to acquire Biogen. However, Samsung BioLogics stated in a regulatory filing yesterday that the rumor is not true.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Janssen Pharmaceutical has recently applied for Biologics License Application for its relapsed or refractory (r/r) multiple myeloma drug. Here’s all about it.
The two companies are already looking at the coming year and seeing the potential for their experimental treatment ofATTR, Eplontersen, formerly known as IONIS-TTR-L.
Part of what is being discovered about the Omicron variant of COVID-19 is how fast it appears to infect people, a median of about three days, compared to four or five with other variants.
Not surprisingly, there’s still plenty of interesting research coming out about COVID-19, but the end of 2021 also provided exciting science in other areas. Here’s a look.
Collegium reached a $2.75 million agreement with a law firm representing 27 U.S. cities, counties and subdivisions related to the opioid crisis and the company’s sale of Xtampza.
The decision to allow the release of Adbry follows positive results from the Phase III ECZTRA trials, which covered almost 2,000 patients living with moderate to severe atopic dermatitis.
BridgeBio Pharma reported topline data from Part A (Month 12) of its Phase III study of acoramidis for symptomatic transthyretin amyloid cardiomyopathy. The drug failed the study arm.
The company was assessing mavrilimumab as a potential therapeutic for COVID-19-related acute respiratory syndrome.
When 2022 rolls around in a little more than a week, some Genentech employees will begin the new year in search of a new job.
The FDA has greenlit Merck and Ridgeback’s molnupiravir under EUA to treat mild to moderate COVID-19 infections in adults at high risk of progression to severe disease.
The report focuses on current and emerging trends in the healthcare industry such as incorporation of IoT and ML to enhance efficiency of medical products.
Studies found that AstraZeneca’s EVUSHELD was still effective against the Omicron variant. EVUSHELD is a long-acting antibody combination made up of tixagevimab and cilgavimab.
Janssen Pharmaceutical says goodbye to San Francisco’s Theravance Biopharma after a disappointing performance from a drug the two companies were developing together.
The latest approvals mark the first time a biologic has been approved for ERA. Cosentyx is also the only biologic approved in the United States for both ERA and PsA in pediatric patients.
New real-world studies from Scotland and England shows that Omicron does not lead to as much hospitalization as Delta. This is consistent with the latest reports from South Africa that say Omicron causes milder disease.
The FDA has approved Novartis’ new drug for lowering bad cholesterol. Leqvio is the first and only siRNA treatment that can reduce low-density lipoprotein cholesterol.
PhaseBio’s move to suspend its Phase IIb trial of pemziviptadil is due to the effect of COVID-19 on manufacturing, associated drug supply, and the rate of enrollment in the study.